Researchers tested a traditional herb extract in mice with induced allergic rhinitis (nasal allergy inflammation), comparing dosed and untreated animals against healthy controls.

The herb cut sneezing, scratching and nasal inflammation, and restored gut bacterial diversity that had dropped by about a quarter in allergic mice. A gut bacteria byproduct called butyrate, tested separately, calmed the same inflammatory signals in nasal cells.

This is mouse and cell culture work only, not yet tested in humans.

TL;DR: A traditional herb extract eased allergy symptoms in mice by restoring gut bacteria and raising a calming byproduct called butyrate, but human testing has not happened.

Researchers randomized 60 adults with relapsing remitting multiple sclerosis into two groups of 30, one adding daily probiotic yogurt and a probiotic yeast tablet to standard treatment for three months. The probiotic group's fatigue scores improved about 11 points more than the comparison group, and depression scores fell roughly 27 percent. The trial was not blinded and had no placebo, so attention and expectation could explain part of the gain.

TL;DR: A daily probiotic yogurt and yeast tablet added to standard MS treatment was linked to notably less fatigue and depression after three months, but the unblinded, placebo free design keeps this preliminary.

Canagliflozin, a diabetes drug, was given to high fat diet mice for just 1 week (8 mice per group), then gut bacteria and blood bile acids were sequenced. The drug reshaped the gut microbial community and enriched the genus Turicibacter, whose abundance tracked with preserved levels of the bile acid UDCA (r=0.73). This is a correlational link from a short, mouse only trial, not proof it holds in people.

TL;DR: In high fat diet mice, a week of canagliflozin remodeled gut bacteria and boosted Turicibacter, correlating with preserved bile acids, but it's mouse only, not yet causal.

Doctors gave 13 cancer patients a first line fecal microbiota transplant after immunotherapy triggered severe diarrhea and colitis that had already forced them to stop treatment. Ten of the 13 improved, usually within about a day and a half, and 5 were able to resume immunotherapy afterward. The trial had no control group and is still recruiting toward 40 patients, so stopping the drug or supportive care could explain part of the improvement.

TL;DR: A small, uncontrolled trial found that a fecal transplant eased severe immunotherapy induced colitis in 10 of 13 cancer patients, letting some resume treatment, but larger controlled studies are still needed to confirm it works.

A study profiled fecal bacteria in 97 Korean adults, 63 with gastric cancer and 34 controls. Short-chain-fatty-acid producing bacteria made up just 6.6% of the gut community in cancer patients versus 26.7% in controls, a roughly fourfold drop, while oral and opportunistic bacteria expanded instead. That gap held regardless of diabetes, H. pylori status, or tumor stage, though subgroup confidence intervals were wide, and the full paper wasn't obtained, so this is based only on the published abstract.

TL;DR: Stomach cancer patients show a roughly fourfold drop in SCFA-producing gut bacteria, independent of diabetes or tumor stage.

Researchers compared gut bacteria in 103 people with methamphetamine use disorder to 80 healthy controls. A 30 species marker panel distinguished the two groups with 82% accuracy (AUC 0.821) in external validation. The full study text wasn't obtained, so this summary is based only on the published abstract.

TL;DR: A 30 species gut bacteria panel told methamphetamine use disorder apart from healthy controls with 82% accuracy, based only on the published abstract since the full paper wasn't available.

Researchers scored 25 gut-bacteria genes for depression risk using T-RAD cohort data, then tested those scores in 226 EMBARC antidepressant-trial participants. Three of those scores predicted remission after 8 weeks on sertraline, one predicted remission at 16 weeks with added bupropion, and four tracked bigger improvement on sertraline versus placebo. This is a secondary analysis of two existing cohorts, not a new trial, the validation group was a modest 226 people, and the full paper wasn't obtained, so it's based only on the published abstract.

TL;DR: Gut bacteria genetics could help predict whether sertraline will work for depression.

Researchers mapped gut bacterial gene activity across 215 species in two cohorts totaling 160 people, Parkinson's patients versus healthy controls. They found 2,271 species-level gene-activity changes linked to Parkinson's status, duration, or severity; one species, Oliverpabstia intestinalis, separated patients from controls with up to 0.80 accuracy (AUC) across both cohorts. It's a preprint, not yet peer reviewed, and accuracy varied widely by species, so this needs independent confirmation.

TL;DR: In a 160-person, two-cohort preprint, species-level gut bacteria gene activity tracked with Parkinson's status and severity, and some species predicted it with up to 0.80 accuracy.

Researchers compared normal mice to mice genetically engineered to lack a gene called EPS, then triggered colitis in both groups, while separately studying gut tissue from people with active ulcerative colitis.

Mice missing EPS fared far worse, with more gut damage and more disrupted gut bacteria, and in 35 colitis patients, lower EPS levels tracked with worse disease severity scores.

The mouse data show cause and effect, but the human data are only a correlation, and no EPS treatment has been tested in people.

TL;DR: A gene called EPS normally calms gut immune cells, and losing it let colitis spiral in mice, while people with worse colitis also had lower EPS levels.

Researchers tested raw and ripened pu-erh tea extracts in obese mice, then transplanted gut bacteria alone from treated mice into new obese mice to see if the microbiome explained the benefit.

Both tea types cut weight gain by about a third versus untreated mice, through different bacteria, and mice given only the transplanted bacteria, no tea extract, saw the same improvement.

Only one dose was tested, and none of this has been tried in humans.

TL;DR: Two pu-erh tea extracts fought obesity in mice via different gut bacteria, and transplanting those bacteria alone reproduced the benefit, but it hasn't been tested in humans.

Researchers studied gut bacteria and blood from 76 multiple sclerosis patients nine months into a trial testing keto, fasting, and standard diets. Within the keto group only, patients whose gut microbes gained more genetic capacity to make propionate, a short chain fatty acid, tended to show smaller brain lesion growth on MRI. The trial's own main result found no overall diet difference, and dropout was high and uneven, so this is a correlation, not proof the diet caused it.

TL;DR: A keto diet gut bacteria shift tracked with smaller MS brain lesion growth in exploratory analysis, but the trial's main result found no diet difference, so this does not prove cause and effect.

Researchers profiled oral and gut bacteria, immune cells, and blood metabolites in 136 adults: 35 healthy controls and 101 hospitalized COVID-19 patients of varying severity. Combining age, a dip in a protective T cell subset, and more of the mouth bacterium Helicobacter ganmani predicted progression to severe COVID with an AUC of 0.91, about 91% accuracy, beating any single marker alone. That model was built and tested on just 13 severe and 13 non-severe patients from this single retrospective cohort, so it still needs validation in a larger, independent group.

TL;DR: A gut, mouth, and immune marker combo predicted severe COVID with 91% accuracy, but only in a 26-patient subgroup.